AbbVie reaches agreement with pan-Canadian alliance for Elahere in platinum-resistant ovarian cancer
ABBV•AbbVie reached an agreement with the Pan-Canadian Pharmaceutical Alliance for Elahere in platinum-resistant ovarian cancer. The company said it looks forward to working with provincial and territorial governments to support timely and equitable public reimbursement.
1. Agreement for Elahere
AbbVie reached an agreement with the Pan-Canadian Pharmaceutical Alliance for Elahere in platinum-resistant ovarian cancer. AbbVie said it looks forward to collaborating with provincial and territorial governments to support timely and equitable public reimbursement of the drug.
